<DOC>
	<DOCNO>NCT02576496</DOCNO>
	<brief_summary>This study evaluate efficacy , safety pharmacokinetics EDO-S101 patient relapsed/refractory hematologic malignancy . All patient receive EDO-S101 .</brief_summary>
	<brief_title>Study EDO-S101 , A First-in-Class Alkylating HDACi Fusion Molecule , Relapsed/Refractory Hematologic Malignancies</brief_title>
	<detailed_description>EDO-S101 new chemical entity , first-in-class fusion molecule alkylator , bendamustine histone-deacetylase inhibitor ( HDACi ) , vorinostat . It anticipate EDO-S101 may activity various hematological malignancy solid tumor . This phase 1 study enroll patient various hematological malignancy . The study consist 2 stage : - Stage 1 : Dose Escalation determine Maximum Tolerated Dose ( MTD ) optimal infusion time pharmacokinetic ( PK ) profile ; expect enroll 21 36 patient - Stage 2 : Expansion four Cohorts , approximately 12 patient enrol per cohort , total 48 patient . In Stage 1 , EDO-S101 dos escalate follow standard 3+3 design . The decision escalate next dose level occur cohort patient complete 3 week ( 21 day ) observation evaluate safety toxicity.The start dose 1 hour infusion 20 mg/m2 , maximum dose level 150 mg/m2 . Reduced infusion time 45 minute 30 minute also assess maximum tolerated dose 1-hour infusion determine . In Stage 2 , four cohort patient ( relapsed/refractory multiple myeloma , relapsed/refractory Hodgkin 's lymphoma , relapsed/refractory peripheral T-cell lymphoma , relapsed/refractory non-Hodgkin 's lymphoma [ except chronic lymphocytic cutaneous T-cell lymphoma ] treat refractory bendamustine ) enrol treat recommended Phase 2 dose ( RP2D ) base result Stage 1 . Treatment occur every 21 day . Patients stage study expect receive median four 3-week Cycles therapy , maximum number treatment Cycles allow 6 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>1 . Execute informed consent . 2 . Patients age ≥18 year sign informed consent . 3 . Diagnosis relapse refractory lymphoid malignancy available therapy . 4 . Discontinuation previous cancer therapy least four ( 4 ) week prior treatment study . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 6 . Neutrophils &gt; 1,000 µL 7 . Platelets ≥75,000 µL 8 . Aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) ≤2.5 upper limit normal ( ULN ) . 9 . Total bilirubin &lt; 2.0 mg/dL unless elevate due know Gilbert 's syndrome . 10 . Creatinine ≤1.5 ULN . 11 . Serum potassium within normal range . 12 . If female childbearing potential ( i.e . postmenopausal surgically sterile ) , must willing abstain sexual intercourse employ effective barrier medical method contraception study drug administration followup period . If male , must sterile willing abstain sexual intercourse employ barrier method contraception study treatment followup period . 1 . Patients primary central nervous system ( CNS ) lymphoma CTCL . 2 . Diagnosis acute leukemia patient treat fludarabine . 3 . Allogeneic stem cell transplant patient patient relapse within 100 day stem cell infusion follow autologous bone marrow transplant . 4 . Patients QTc interval &gt; 450 msec . 5 . Patients treatment drug know prolong QT/QTc interval . 6 . Any serious medical condition interferes adherence study procedure . 7 . Patients history second malignancy diagnose within three ( 3 ) year study enrollment exclude basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . 8 . Pregnant breast feeding female . 9 . New York Heart Association ( NYHA ) stage III/IV congestive heart failure , arrhythmias adequately control , active infection , significant comorbidities [ e.g . active central nervous system metastases and/or carcinomatous meningitis , active infection require systemic therapy , history human immunodeficiency virus ( HIV ) infection , active Hepatitis B Hepatitis C. 10 . Chemotherapy , radiotherapy , biologics , and/or treatment immunotherapy complete four ( 4 ) week prior first dose study drug without complete recovery treatment . 11 . Use investigational agent 30 day prior Screening Visit discontinuation study drug . 12 . Steroid treatment within seven ( 7 ) day prior study treatment . Patients require intermittent use bronchodilator , topical steroid local steroid injection exclude study . Patients stabilize 10 mg PO QD less seven ( 7 ) day prior study drug administration allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>phase 1 clinical trial</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>Hodgkin 's lymphoma</keyword>
	<keyword>peripheral T-cell lymphoma</keyword>
	<keyword>non-Hodgkin 's lymphoma</keyword>
</DOC>